Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alligator, Atom, China Medical Systems, Hepion, Medac, Medexus, Merus, Partner, Pharma Two B, Pulmokine, Sernova, Xoma.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Autolus, Galderma, Gilead, Hua, Maplight, Merus, MBX, Revolution Medicines, Senti, Soligenix.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. won local approval of the first China-made trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC), sacituzumab tirumotecan, as a third-line therapy for advanced breast cancer.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advanz, Anavex, Aop Orphan, Beigene, Cevomed, Exelixis, Gsk, Kelun-Biotech, Lin, Novartis, Oncopeptides, Satsuma, Tuhura, Valneva.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acadia, Adcendo, Agenus, Alector, Duality Biologics, Empyrean, Eos, Idorsia, Kronos, PTC, Saniona.